Skip to main content
Medical information Clinical review pending

Genetic Testing

PRKAG2 Gene Cardiomyopathy Familial Hypertrophic Type 6 Genetic Test

Genetic test to identify mutations in the PRKAG2 gene associated with Familial Hypertrophic Cardiomyopathy (FHC). Helps assess risk for individuals with a family history of heart conditions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or dried blood spot on FTA card.
Results
Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. A genetic counseling session is recommended prior to testing to discuss clinical history and family pedigree.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the PRKAG2 Gene Cardiomyopathy Familial Hypertrophic Type 6 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of hypertrophic cardiomyopathy
  • ✓Symptoms suggestive of heart disease (e.g., shortness of breath, chest pain, fainting)
  • ✓Personal history of unexplained heart conditions
  • ✓Family member diagnosed with PRKAG2-related cardiomyopathy
  • ✓Genetic counseling for individuals with relevant family history
02

In plain language

What this test helps you understand

Identifies specific mutations in the PRKAG2 gene associated with Familial Hypertrophic Cardiomyopathy Type 6. Helps in risk assessment and management for individuals with a family history of the condition.
The PRKAG2 Gene Cardiomyopathy Familial Hypertrophic Type 6 NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to a specific type of hypertrophic cardiomyopathy (FHC). This condition involves the thickening of the heart muscle and can lead to serious heart problems. Early detection through genetic testing is important for managing potential risks.

This test focuses on the PRKAG2 gene, which is known to be involved in heart function. Using Next Generation Sequencing (NGS) technology, we can detect specific changes (mutations) in this gene that may increase a person's risk of developing hypertrophic cardiomyopathy.

Individuals with a family history of hypertrophic cardiomyopathy or related heart conditions may benefit from this test. If you or a family member experience symptoms like unexplained shortness of breath, chest pain, dizziness, or fainting, discussing this test with your doctor is advisable. It is also recommended for those with known relatives diagnosed with PRKAG2-related conditions.

Understanding the results requires consultation with a healthcare professional. A positive result may indicate a genetic predisposition, guiding further medical management. A negative result can provide reassurance but does not eliminate all risks. Discussing the implications with a genetic counselor or cardiologist is essential.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. A genetic counseling session is recommended prior to testing to discuss clinical history and family pedigree.
SampleBlood sample (EDTA tube), extracted DNA, or dried blood spot on FTA card.
MethodologyNext Generation Sequencing (NGS) analysis of the PRKAG2 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only analyzes the PRKAG2 gene. Other genes can also cause hypertrophic cardiomyopathy. A negative result does not completely rule out a genetic predisposition. The test may not detect all possible mutations within the PRKAG2 gene.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

FHC is a genetic heart condition where the heart muscle becomes abnormally thick, which can affect the heart's ability to pump blood effectively.
Individuals with a family history of FHC, unexplained heart symptoms, or a known family member with a PRKAG2 mutation should consider this test.
A positive result indicates the presence of a mutation in the PRKAG2 gene associated with FHC. It suggests an increased risk and warrants further medical evaluation.
A negative result means no mutations associated with FHC were found in the PRKAG2 gene. However, other genetic factors or genes could be involved.
Yes, genetic counseling before and after the test is highly recommended to understand the implications of the test and its results.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp